Clinical trials: MZL
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°)
Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP
The goal of this study is to evaluate efficacy and safety of the combination of lenalidomide, an immunomodulatory drug (IMiD) with a standard immunochemotherapy treatment, called R-DHAP.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma Grade III (FL III°), Mantle Cell Lymphoma (MCL), Blastoid Variant, Burkitt Lymphoma (BL)
- Trial name
- R²-DHAP (NCT02983097)
- Testing
- Rituximab, Cisplatin, Carboplatin
- Where
- 12 sites in Germany
- Volunteers
- 34 people
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0
To determine whether peripheral blood flow cytometry can reduce or replace invasive bone marrow examinations in patients with slow growing lymphomas.
- Conditions
- Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL)
- Trial name
- BMPB (NCT03265158)
- Where
- 2 sites in United Kingdom
- Volunteers
- 108 people
- Sponsor
- Royal Marsden NHS Foundation Trust